BR0212989A - Métodos para tratamento neuroprotetor usando inibidores de inos seletivos - Google Patents
Métodos para tratamento neuroprotetor usando inibidores de inos seletivosInfo
- Publication number
- BR0212989A BR0212989A BR0212989-2A BR0212989A BR0212989A BR 0212989 A BR0212989 A BR 0212989A BR 0212989 A BR0212989 A BR 0212989A BR 0212989 A BR0212989 A BR 0212989A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- selective inhibitors
- treatment
- neuroprotective
- neuroprotective treatment
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 230000000324 neuroprotective effect Effects 0.000 title abstract 3
- 229940124639 Selective inhibitor Drugs 0.000 title abstract 2
- 229940119568 Inducible nitric oxide synthase inhibitor Drugs 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/961,521 US20030119826A1 (en) | 2001-09-24 | 2001-09-24 | Neuroprotective treatment methods using selective iNOS inhibitors |
| PCT/US2002/030214 WO2003026638A1 (en) | 2001-09-24 | 2002-09-24 | Neuroprotective treatment methods using selective inos inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0212989A true BR0212989A (pt) | 2005-04-26 |
Family
ID=25504581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0212989-2A BR0212989A (pt) | 2001-09-24 | 2002-09-24 | Métodos para tratamento neuroprotetor usando inibidores de inos seletivos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20030119826A1 (enExample) |
| EP (1) | EP1429752A1 (enExample) |
| JP (1) | JP2005508910A (enExample) |
| KR (1) | KR20040039394A (enExample) |
| CN (1) | CN1556698A (enExample) |
| AU (1) | AU2002327042A2 (enExample) |
| BR (1) | BR0212989A (enExample) |
| CA (1) | CA2455989A1 (enExample) |
| IL (1) | IL161005A0 (enExample) |
| MX (1) | MXPA04002710A (enExample) |
| PL (1) | PL371774A1 (enExample) |
| WO (1) | WO2003026638A1 (enExample) |
| ZA (1) | ZA200402288B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8314124B2 (en) * | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
| CN107176923A (zh) * | 2005-10-19 | 2017-09-19 | 泰华制药工业有限公司 | 拉奎尼莫钠晶体及其制备方法 |
| KR101495327B1 (ko) | 2006-06-12 | 2015-02-24 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| US8178127B2 (en) | 2007-12-20 | 2012-05-15 | Teva Pharmaceuticals Industries, Ltd. | Stable laquinimod preparations |
| CA2736091A1 (en) * | 2008-09-03 | 2010-03-11 | Teva Pharmaceutical Industries Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
| CN105616410A (zh) * | 2009-07-30 | 2016-06-01 | 泰华制药工业有限公司 | 利用拉喹莫德治疗克隆氏病 |
| ES2731052T3 (es) * | 2009-08-10 | 2019-11-13 | Active Biotech Ab | Tratamiento de la enfermedad de Huntington usando laquinimod |
| SG11201401330YA (en) | 2011-10-12 | 2014-05-29 | Teva Pharma | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| US9161935B2 (en) | 2012-02-03 | 2015-10-20 | Teva Pharmaceutical Industries, Ltd. | Use of laquinimod for treating Crohn's disease patients who failed first-line anti-TNF therapy |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| CA2890194A1 (en) | 2012-11-07 | 2014-05-15 | Teva Pharmaceutical Industries Ltd. | Amine salts of laquinimod |
| WO2014153145A2 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100835265B1 (ko) * | 2000-03-24 | 2008-06-09 | 파마시아 코포레이션 | 산화 질소 신타아제 억제제로 유용한 아미디노 화합물 및그들의 염 |
| AR032318A1 (es) * | 2000-04-13 | 2003-11-05 | Pharmacia Corp | Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa |
-
2001
- 2001-09-24 US US09/961,521 patent/US20030119826A1/en not_active Abandoned
-
2002
- 2002-09-24 WO PCT/US2002/030214 patent/WO2003026638A1/en not_active Ceased
- 2002-09-24 AU AU2002327042A patent/AU2002327042A2/en not_active Abandoned
- 2002-09-24 IL IL16100502A patent/IL161005A0/xx unknown
- 2002-09-24 JP JP2003530275A patent/JP2005508910A/ja active Pending
- 2002-09-24 BR BR0212989-2A patent/BR0212989A/pt not_active IP Right Cessation
- 2002-09-24 EP EP02761804A patent/EP1429752A1/en not_active Withdrawn
- 2002-09-24 KR KR10-2004-7004170A patent/KR20040039394A/ko not_active Withdrawn
- 2002-09-24 MX MXPA04002710A patent/MXPA04002710A/es unknown
- 2002-09-24 CN CNA028185935A patent/CN1556698A/zh active Pending
- 2002-09-24 PL PL02371774A patent/PL371774A1/xx not_active Application Discontinuation
- 2002-09-24 CA CA002455989A patent/CA2455989A1/en not_active Abandoned
-
2004
- 2004-03-23 ZA ZA200402288A patent/ZA200402288B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2455989A1 (en) | 2003-04-03 |
| ZA200402288B (en) | 2006-12-27 |
| PL371774A1 (en) | 2005-06-27 |
| JP2005508910A (ja) | 2005-04-07 |
| WO2003026638A1 (en) | 2003-04-03 |
| US20030119826A1 (en) | 2003-06-26 |
| KR20040039394A (ko) | 2004-05-10 |
| IL161005A0 (en) | 2004-08-31 |
| MXPA04002710A (es) | 2004-07-05 |
| CN1556698A (zh) | 2004-12-22 |
| AU2002327042A2 (en) | 2003-04-07 |
| EP1429752A1 (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9911666A (pt) | Combinação farmacêutica, uso da combinação, processo para tratamento de uma doença inflamatória em uma pessoa sofrendo de ou susceptìvel a tal doença, e, composição farmacêutica | |
| BR9812753A (pt) | Combinação farmacêutica, uso da mesma, processo para tratamento de uma doença inflamatória, e, composição farmacêutica | |
| BR0313282A (pt) | Composições de inibidor seletivo de ciclooxigenase-2 e um inibidor de anidrase carbÈnica para o tratamento de neoplasia | |
| BR0013122A (pt) | Ciclobenzaprina para tratamento de distúrbio de ansiedade generalizado e composições de ciclobenzaprina | |
| BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
| BRPI0013478B8 (pt) | medicamento compreendendo inibidor pde e uso de roflumilast | |
| BR0206639A (pt) | Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares | |
| BR0306872A (pt) | Composições e métodos de tratamento envolvendo agonistas do receptor-gama ativado pelo proliferador de peroxissoma e inibidores seletivos da ciclooxigenase-2 | |
| BRPI0308663B8 (pt) | uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas | |
| BR0212989A (pt) | Métodos para tratamento neuroprotetor usando inibidores de inos seletivos | |
| BR0212907A (pt) | Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis | |
| BRPI0415753A (pt) | método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm | |
| BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
| WO2008042480A3 (en) | Epoxide inhibitors of cysteine proteases | |
| BRPI0411864A (pt) | combinação de inibidores de src quinase e agentes quimioterápicos para o tratamento de doenças proliferativas | |
| WO2002039994A3 (en) | Methods for the treatment and prevention of urinary stone disease | |
| BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
| BR0313413A (pt) | Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer | |
| AU7862401A (en) | Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer | |
| BR0314300A (pt) | Aplicação de substâncias para a proteção da pele | |
| MXPA04006418A (es) | Composicion que comprende por lo menos una oxazolina para inhibir la migracion de celulas de langerhans y usos de la misma. | |
| BR0012058A (pt) | Combinação sinérgica: gabapentina e pregabalina | |
| WO2005039483A3 (en) | Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity | |
| BR0317947A (pt) | Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1971 DE 14/10/2008. |